RemeGen Co., Ltd. (9995.HK)
HKD 15.52
(-0.26%)
HKD 15.52
(-0.26%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.5 Billion CNY | -55.62% |
| 2022 | -993.06 Million CNY | -452.25% |
| 2021 | 281.92 Million CNY | 142.17% |
| 2020 | -668.54 Million CNY | -72.92% |
| 2019 | -386.62 Million CNY | -67.11% |
| 2018 | -231.35 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -426.59 Million CNY | -27.38% |
| 2024 Q1 | -334.9 Million CNY | 31.5% |
| 2023 Q3 | -315.44 Million CNY | 20.49% |
| 2023 FY | -1.54 Billion CNY | -55.62% |
| 2023 Q4 | -488.93 Million CNY | -55.0% |
| 2023 Q2 | -396.75 Million CNY | -19.49% |
| 2023 Q1 | -332.04 Million CNY | -8.58% |
| 2022 Q3 | -205.89 Million CNY | 9.17% |
| 2022 Q1 | -291.01 Million CNY | -135.74% |
| 2022 Q2 | -226.68 Million CNY | 22.11% |
| 2022 FY | -993.06 Million CNY | -452.25% |
| 2022 Q4 | -305.81 Million CNY | -48.52% |
| 2021 Q3 | -224.5 Million CNY | 17.07% |
| 2021 Q1 | -197.51 Million CNY | 13.74% |
| 2021 FY | 281.92 Million CNY | 142.17% |
| 2021 Q2 | -270.71 Million CNY | -37.06% |
| 2021 Q4 | 814.33 Million CNY | 462.72% |
| 2020 Q3 | -228.98 Million CNY | -47.13% |
| 2020 Q4 | -228.98 Million CNY | 0.0% |
| 2020 Q2 | -155.63 Million CNY | -59.05% |
| 2020 Q1 | -97.85 Million CNY | 18.51% |
| 2020 FY | -668.54 Million CNY | -72.92% |
| 2019 Q1 | -77.88 Million CNY | 19.4% |
| 2019 FY | -386.62 Million CNY | -67.11% |
| 2019 Q4 | -120.07 Million CNY | 0.0% |
| 2019 Q3 | -120.07 Million CNY | -12.5% |
| 2019 Q2 | -106.73 Million CNY | -37.04% |
| 2018 Q4 | -96.62 Million CNY | 0.0% |
| 2018 Q2 | -57.47 Million CNY | 0.0% |
| 2018 Q1 | -57.47 Million CNY | 0.0% |
| 2018 FY | -231.35 Million CNY | 0.0% |
| 2017 Q4 | -57.47 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 67.76 Million HKD | 2315.69% |
| CK Life Sciences Int'l., (Holdings) Inc. | 897.95 Million HKD | 267.217% |